Pathological gambling in Parkinson's disease—a review of the literature |
| |
| Authors: | Atbin Djamshidian MD Francisco Cardoso MD PhD Donald Grosset MD FRCP Henrietta Bowden‐Jones MD Andrew J. Lees MD FRCP |
| |
| Affiliation: | 1. Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom;2. Movement Disorders Group, Neurology Service, Department of Internal Medicine, Federal University of Minas Gerais, Minas Gerais, Brazil;3. Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom;4. CNWL National Problem Gambling Clinic, London, United Kingdom;5. Imperial College London, London, United Kingdom |
| |
| Abstract: | The prevalence of pathological gambling is 3.4% to 6% in treated Parkinson's disease, which is higher than the background population rate. In this review we discuss current evidence to indicate that dopamine agonists are much more likely to trigger this behavior than either L ‐dopa or selective monoamine oxidase B inhibitor monotherapy. New insights from recent behavioral and functional imaging studies and possible treatment approaches are also covered. A PubMed literature search using the terms “gambling” and “Parkinson's disease,” “impulse control disorder,” “impulsive compulsive behaviour,” “dopamine agonist,” of individual dopamine agonists, and of ongoing drug trials, using http://www.clinicaltrials.gov , was carried out for the period up to January 2011. © 2011 Movement Disorder Society |
| |
| Keywords: | Parkinson's disease pathological gambling dopamine agonists impulse control adverse effects compulsions |
|
|
